Genfit S.A.

OTCPK:GNFT.Y 주식 리포트

시가총액: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit 경영진

경영진 기준 점검 3/4

Genfit CEO는 M. Prigent, Sep2019 에 임명되었습니다 의 임기는 6.5 년입니다. 총 연간 보상은 €681.95K, 59.5% 급여 및 40.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $333.78K 가치에 해당하는 회사 주식의 0.062% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4 년과 8.8 년입니다.

핵심 정보

M. Prigent

최고경영자

€681.9k

총 보수

CEO 급여 비율59.47%
CEO 재임 기간6.5yrs
CEO 지분 보유율0.06%
경영진 평균 재임 기간4yrs
이사회 평균 재임 기간8.8yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

CEO 보수 분석

M. Prigent의 보수는 Genfit의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Jun 30 2025n/an/a

-€39m

Mar 31 2025n/an/a

-€19m

Dec 31 2024€682k€406k

€2m

Sep 30 2024n/an/a

€12m

Jun 30 2024n/an/a

€22m

Mar 31 2024n/an/a

-€3m

Dec 31 2023€664k€394k

-€29m

Sep 30 2023n/an/a

-€32m

Jun 30 2023n/an/a

-€34m

Mar 31 2023n/an/a

-€29m

Dec 31 2022€632k€375k

-€24m

Sep 30 2022n/an/a

€12m

Jun 30 2022n/an/a

€48m

Mar 31 2022n/an/a

€58m

Dec 31 2021€562k€325k

€67m

Sep 30 2021n/an/a

€14m

Jun 30 2021n/an/a

-€39m

Mar 31 2021n/an/a

-€70m

Dec 31 2020€455k€325k

-€101m

Sep 30 2020n/an/a

-€84m

Jun 30 2020n/an/a

-€67m

Mar 31 2020n/an/a

-€66m

Dec 31 2019€325k€95k

-€65m

보상 대 시장: M.의 총 보수(USD792.04K)는 US 시장에서 비슷한 규모 기업의 평균(USD2.48M)보다 낮습니다.

보상과 수익: M.의 보상은 회사가 적자임에도 증가했습니다.

CEO

M. Prigent (57 yo)

6.5yrs
재임 기간
€681,945
보수

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

리더십 팀

이름직위재임 기간보수지분
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
M. Prigent
Chief Executive Officer6.5yrs€681.95k0.062%
$ 333.8k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno data데이터 없음데이터 없음
Thomas Baetz
Chief Financial Officer4.9yrs데이터 없음데이터 없음
Pascal Caisey
Chief Operating Officer4yrs데이터 없음0.0030%
$ 16.3k
Sakina Sayah-Jeanne
Chief Scientific Officerless than a year데이터 없음데이터 없음
Jean-Christophe Marcoux
Chief Corporate Affairs Officer3yrs데이터 없음0.0094%
$ 50.8k
Laurent Lannoo
Corporate Secretary & Director of Legal Affairs18.2yrs데이터 없음0.023%
$ 122.1k
Stefanie Magner
Chief Compliance Officer & Executive VP of International Legal Affairs5yrs데이터 없음0.0055%
$ 30.0k
Emilie Desodt
Executive Vice President of Human Resources4yrs데이터 없음0.00047%
$ 2.5k
John Brozek
Executive Vice President of Data & Information Technology3yrs데이터 없음0.0060%
$ 32.7k
Tom Huijbers
Executive Vice President of Regulatory3yrs데이터 없음데이터 없음
4.0yrs
평균 재임 기간
53yo
평균 나이

경험이 풍부한 관리: GNFT.Y의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4 년).

이사회 구성원

이름직위재임 기간보수지분
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno data데이터 없음데이터 없음
Philippe Moons
Board Observer5.1yrs€14.17k0.0021%
$ 11.3k
Florence Séjourné
Director8.8yrs데이터 없음데이터 없음
Scott L. Friedman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Arun Sanyal
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Trauner
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Catherine Larue
Independent Director8.8yrs€50.14k데이터 없음
Vlad Ratziu
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Anne-Helene Monsellato
Independent Director8.8yrs€45.78k데이터 없음
Katherine Kalin
Independent Director5.7yrs€38.39k0.010%
$ 54.3k
Eric Baclet
Independent Vice-Chairman of the Board5.7yrs€68.42k0.0024%
$ 13.0k
8.8yrs
평균 재임 기간
63yo
평균 나이

경험이 풍부한 이사회: GNFT.Y의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.8 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/03/11 23:24
종가2026/03/09 00:00
수익2025/06/30
연간 수익2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Genfit S.A.는 14명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank